Does the media prefer AMGN or REGN?

In the previous week, Amgen had 3 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 28 mentions for Amgen and 25 mentions for Regeneron Pharmaceuticals. Amgen's average media sentiment score of 1.27 beat Regeneron Pharmaceuticals' score of 0.76 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 22 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Regeneron Pharmaceuticals 11 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media refer more to GILD or REGN?

In the previous week, Gilead Sciences had 11 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 36 mentions for Gilead Sciences and 25 mentions for Regeneron Pharmaceuticals. Gilead Sciences' average media sentiment score of 1.47 beat Regeneron Pharmaceuticals' score of 0.76 indicating that Gilead Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 32 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Regeneron Pharmaceuticals 11 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media prefer MRNA or REGN?

In the previous week, Regeneron Pharmaceuticals had 20 more articles in the media than Moderna. MarketBeat recorded 25 mentions for Regeneron Pharmaceuticals and 5 mentions for Moderna. Regeneron Pharmaceuticals' average media sentiment score of 0.76 beat Moderna's score of 0.32 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Regeneron Pharmaceuticals 11 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media prefer NTLA or REGN?

In the previous week, Regeneron Pharmaceuticals had 23 more articles in the media than Intellia Therapeutics. MarketBeat recorded 25 mentions for Regeneron Pharmaceuticals and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.47 beat Regeneron Pharmaceuticals' score of 0.76 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regeneron Pharmaceuticals 11 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media refer more to REGN or VIR?

In the previous week, Regeneron Pharmaceuticals had 20 more articles in the media than Vir Biotechnology. MarketBeat recorded 25 mentions for Regeneron Pharmaceuticals and 5 mentions for Vir Biotechnology. Regeneron Pharmaceuticals' average media sentiment score of 0.76 beat Vir Biotechnology's score of 0.54 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 11 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Vir Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Regeneron Pharmaceuticals (REGN) Competitors

$614.78 0.00 (0.00%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$616.12 +1.34 (+0.22%)

As of 05/29/2026 07:51 PM Eastern

Compare

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

Should you buy Regeneron Pharmaceuticals stock or one of its competitors? MarketBeat compares Regeneron Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Intellia Therapeutics (NTLA), and Vir Biotechnology (VIR). These companies are all part of the "med - biomed/gene" industry.

How does Regeneron Pharmaceuticals compare to Amgen?

Amgen (NASDAQ:AMGN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Amgen presently has a consensus target price of $355.19, suggesting a potential upside of 5.46%. Regeneron Pharmaceuticals has a consensus target price of $792.65, suggesting a potential upside of 28.93%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.48
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.70

76.5% of Amgen shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.9% of Amgen shares are held by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Amgen has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market.

Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$36.75B	4.95	$7.71B	$14.37	23.44
Regeneron Pharmaceuticals	$14.34B	4.53	$4.50B	$41.04	14.98

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Amgen's net margin of 20.96%. Amgen's return on equity of 137.41% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	20.96%	137.41%	13.28%
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 3.0%. Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.6%. Amgen pays out 70.1% of its earnings in the form of a dividend. Regeneron Pharmaceuticals pays out 9.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Amgen had 3 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 28 mentions for Amgen and 25 mentions for Regeneron Pharmaceuticals. Amgen's average media sentiment score of 1.27 beat Regeneron Pharmaceuticals' score of 0.76 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	22 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	11 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

Amgen beats Regeneron Pharmaceuticals on 11 of the 19 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

Gilead Sciences has higher revenue and earnings than Regeneron Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	5.67	$8.51B	$7.34	18.31
Regeneron Pharmaceuticals	$14.34B	4.53	$4.50B	$41.04	14.98

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Gilead Sciences has a net margin of 30.99% compared to Regeneron Pharmaceuticals' net margin of 29.65%. Gilead Sciences' return on equity of 48.19% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	30.99%	48.19%	18.28%
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%

Gilead Sciences presently has a consensus target price of $156.93, indicating a potential upside of 16.73%. Regeneron Pharmaceuticals has a consensus target price of $792.65, indicating a potential upside of 28.93%. Given Regeneron Pharmaceuticals' higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.70

Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.4%. Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share and has a dividend yield of 0.6%. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. Regeneron Pharmaceuticals pays out 9.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has increased its dividend for 10 consecutive years. Gilead Sciences is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Gilead Sciences has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market.

In the previous week, Gilead Sciences had 11 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 36 mentions for Gilead Sciences and 25 mentions for Regeneron Pharmaceuticals. Gilead Sciences' average media sentiment score of 1.47 beat Regeneron Pharmaceuticals' score of 0.76 indicating that Gilead Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	32 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	11 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

Gilead Sciences beats Regeneron Pharmaceuticals on 15 of the 20 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Moderna?

Moderna (NASDAQ:MRNA) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Regeneron Pharmaceuticals has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	9.63	-$2.82B	-$8.15	N/A
Regeneron Pharmaceuticals	$14.34B	4.53	$4.50B	$41.04	14.98

Moderna currently has a consensus price target of $35.73, indicating a potential downside of 24.28%. Regeneron Pharmaceuticals has a consensus price target of $792.65, indicating a potential upside of 28.93%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.70

75.3% of Moderna shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Moderna has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Moderna's net margin of -143.55%. Regeneron Pharmaceuticals' return on equity of 13.16% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%

In the previous week, Regeneron Pharmaceuticals had 20 more articles in the media than Moderna. MarketBeat recorded 25 mentions for Regeneron Pharmaceuticals and 5 mentions for Moderna. Regeneron Pharmaceuticals' average media sentiment score of 0.76 beat Moderna's score of 0.32 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Regeneron Pharmaceuticals	11 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

Regeneron Pharmaceuticals beats Moderna on 14 of the 17 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Intellia Therapeutics currently has a consensus price target of $20.25, suggesting a potential upside of 43.92%. Regeneron Pharmaceuticals has a consensus price target of $792.65, suggesting a potential upside of 28.93%. Given Intellia Therapeutics' higher possible upside, analysts clearly believe Intellia Therapeutics is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.70

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Intellia Therapeutics' net margin of -597.04%. Regeneron Pharmaceuticals' return on equity of 13.16% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%

In the previous week, Regeneron Pharmaceuticals had 23 more articles in the media than Intellia Therapeutics. MarketBeat recorded 25 mentions for Regeneron Pharmaceuticals and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.47 beat Regeneron Pharmaceuticals' score of 0.76 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	11 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has higher revenue and earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	29.05	-$412.69M	-$3.54	N/A
Regeneron Pharmaceuticals	$14.34B	4.53	$4.50B	$41.04	14.98

88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 3.1% of Intellia Therapeutics shares are owned by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Intellia Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

Summary

Regeneron Pharmaceuticals beats Intellia Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

Regeneron Pharmaceuticals has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market.

Regeneron Pharmaceuticals has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	4.53	$4.50B	$41.04	14.98
Vir Biotechnology	$68.56M	23.47	-$437.99M	-$3.13	N/A

In the previous week, Regeneron Pharmaceuticals had 20 more articles in the media than Vir Biotechnology. MarketBeat recorded 25 mentions for Regeneron Pharmaceuticals and 5 mentions for Vir Biotechnology. Regeneron Pharmaceuticals' average media sentiment score of 0.76 beat Vir Biotechnology's score of 0.54 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	11 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Vir Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has a net margin of 29.65% compared to Vir Biotechnology's net margin of -638.88%. Regeneron Pharmaceuticals' return on equity of 13.16% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	29.65%	13.16%	10.17%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Regeneron Pharmaceuticals presently has a consensus target price of $792.65, indicating a potential upside of 28.93%. Vir Biotechnology has a consensus target price of $20.25, indicating a potential upside of 112.26%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe Vir Biotechnology is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.70
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Regeneron Pharmaceuticals beats Vir Biotechnology on 13 of the 17 factors compared between the two stocks.

Get Regeneron Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

REGN vs. The Competition

Export

Metric	Regeneron Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$64.99B	$3.40B	$6.41B	$12.57B
Dividend Yield	0.61%	2.29%	2.68%	5.31%
P/E Ratio	14.98	18.88	21.61	26.27
Price / Sales	4.53	334.85	561.77	114.93
Price / Cash	14.65	54.19	27.44	37.60
Price / Book	2.08	6.93	10.04	6.86
Net Income	$4.50B	$24.20M	$3.56B	$337.26M
7 Day Performance	-3.77%	4.11%	2.82%	3.58%
1 Month Performance	N/A	N/A	N/A	-0.79%
1 Year Performance	24.64%	66.00%	37.62%	39.67%

Regeneron Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
REGN Regeneron Pharmaceuticals	4.9217 of 5 stars	$614.78 flat	$792.65 +28.9%	+24.6%	$64.99B	$14.34B	14.98	15,410	Trending News High Trading Volume
AMGN Amgen	4.2202 of 5 stars	$331.57 +0.2%	$355.19 +7.1%	+17.3%	$178.94B	$37.22B	23.07	31,500	Positive News
GILD Gilead Sciences	4.7629 of 5 stars	$130.69 +0.1%	$156.93 +20.1%	+21.8%	$162.26B	$29.74B	17.81	17,000	Positive News
MRNA Moderna	1.4824 of 5 stars	$48.12 +5.2%	$35.73 -25.7%	+77.7%	$19.09B	$2.20B	N/A	4,700
NTLA Intellia Therapeutics	3.0769 of 5 stars	$12.26 +2.7%	$20.25 +65.2%	+101.3%	$1.71B	$66.09M	N/A	600	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:REGN) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regeneron Pharmaceuticals (REGN) Competitors

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

How does Regeneron Pharmaceuticals compare to Amgen?

Summary

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Summary

How does Regeneron Pharmaceuticals compare to Moderna?

Summary

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Summary

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REGN vs. The Competition

Regeneron Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Regeneron Pharmaceuticals (REGN) Competitors

REGN vs. AMGN, GILD, MRNA, NTLA, and VIR

How does Regeneron Pharmaceuticals compare to Amgen?

Do analysts prefer AMGN or REGN?

Do institutionals & insiders hold more shares of AMGN or REGN?

Which has more risk and volatility, AMGN or REGN?

Which has stronger valuation & earnings, AMGN or REGN?

Is AMGN or REGN more profitable?

Is AMGN or REGN a better dividend stock?

Does the media prefer AMGN or REGN?

Summary

How does Regeneron Pharmaceuticals compare to Gilead Sciences?

Which has preferable valuation and earnings, GILD or REGN?

Do insiders and institutionals have more ownership in GILD or REGN?

Is GILD or REGN more profitable?

Do analysts prefer GILD or REGN?

Is GILD or REGN a better dividend stock?

Which has more volatility and risk, GILD or REGN?

Does the media refer more to GILD or REGN?

Summary

How does Regeneron Pharmaceuticals compare to Moderna?

Which has better valuation & earnings, MRNA or REGN?

Do analysts rate MRNA or REGN?

Do institutionals and insiders hold more shares of MRNA or REGN?

Which has more risk and volatility, MRNA or REGN?

Is MRNA or REGN more profitable?

Does the media prefer MRNA or REGN?

Summary

How does Regeneron Pharmaceuticals compare to Intellia Therapeutics?

Do analysts rate NTLA or REGN?

Is NTLA or REGN more profitable?

Does the media prefer NTLA or REGN?

Which has stronger earnings and valuation, NTLA or REGN?

Do institutionals and insiders have more ownership in NTLA or REGN?

Which has more risk and volatility, NTLA or REGN?

Summary

How does Regeneron Pharmaceuticals compare to Vir Biotechnology?

Which has more volatility & risk, REGN or VIR?

Which has better valuation and earnings, REGN or VIR?

Does the media refer more to REGN or VIR?

Is REGN or VIR more profitable?

Do insiders & institutionals believe in REGN or VIR?

Do analysts rate REGN or VIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REGN vs. The Competition

Regeneron Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools